US3918905A - Diagnostic test for the determination of sickling hemoglobinopathies - Google Patents

Diagnostic test for the determination of sickling hemoglobinopathies Download PDF

Info

Publication number
US3918905A
US3918905A US381299A US38129973A US3918905A US 3918905 A US3918905 A US 3918905A US 381299 A US381299 A US 381299A US 38129973 A US38129973 A US 38129973A US 3918905 A US3918905 A US 3918905A
Authority
US
United States
Prior art keywords
percent
total solids
hemoglobin
aqueous phase
amounts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US381299A
Inventor
Bert Warren
Jr Gordon Crosby
George L Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BHP DIAGNOSTIX Inc A CORP OF
Biological Corp of America
Original Assignee
Biological Corp of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological Corp of America filed Critical Biological Corp of America
Priority to US381299A priority Critical patent/US3918905A/en
Application granted granted Critical
Publication of US3918905A publication Critical patent/US3918905A/en
Assigned to BHP DIAGNOSTIX, INC., A CORP OF DE reassignment BHP DIAGNOSTIX, INC., A CORP OF DE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: COOPERBIOMEDICAL, INC. A DE CORP
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin

Definitions

  • ABSTRACT A novel composition comprising an aqueous and an organic phase.
  • the aqueous phase comprising essentially a phosphate buffering system containing a stable reducing agent and a lysing agent.
  • the composition providing for a test for the determination of sickling hemoglobin that is simple to perform. is stable. convenient. reliable. fast and one that differentiates between heteroz gous Hemoglobin S and homozygous Hemoglobin 5 without false positives or false negatnes.
  • the procedure facilitates unit packaging at a manufacturers level, is simple and rapid, provides for reagent stability of up to 2 months, has an endpoint stability which provides for reading the results even after periods of up to 6 weeks, does not require the use of any viewing devices and affords the presumptive identification of normal (AA), trait (AS), and disease (SS) hemoglobin genotypes with an increase in reliability.
  • the instant invention has possible application for the determination of such blood characteristics in newbrons.
  • the composition has value for rapidly screening samples newborns. routine practice, for medical emergencies and in the practice of pediatric medicine.
  • the composition is comprised of an aqueous phase containing a phosphate buffer system, a stable reducing agent system and a lysing agent, said aqueous phase being in combination with an organic phase which is immiscible with the aqueous phase.
  • this invention relates to a twophase composition comprised of an aqueous phase and an organic phase wherein the aqueous phase is comprised of about 38-45 percent solids (on a weight- [volume basis) having a hydrogen ion content sufficient to provide a pH value of about 6.3 said solids being comprised of (a) a lysing agent providing for up to about 2 percent of the total solids content (b) a mixture of chemical reducing agents providing for up to about 22.4 percent of the total solids content and (c) a phosphate ion bufier system providing the remaining total solids (75.6 percent) present in the aqueous phase.
  • the phosphate ion is provided by dibasic alkali metal phosphate (preferably dibasic potassium phosphate) and monobasic alkali metal phosphate (preferably monobasic potassium phosphate) in the weight/- weight ration of 1.75 of the dibasic phosphate to 1.0 of the monobasic phosphate.
  • the organic phase added after the aqueous phase has been aliquoted, is preferably in the volume/volume ration of 1 part organic phase to 4 parts aqueous phase. Although minor variations are possible, it is preferred to employ a total solids content in the aqueous phase within the range of 38-45percent solids, with 41 percent being most preferred.
  • the most preferred 2 stable chemical reducing system is provided for by combining sodium hydrosulfite and sodium bisulfite in the sodium hydrosulfite/sodium bisulfite ratio of l/ 10 (wt./wt.).
  • the preparation of the most preferred formulation is effected by adding (a) 237 gms. of dibasic potassium phosphate, (b) l35 gm. of monobasic potassium phosphate, (c) 10 gm. of sodium hydrosulfite and (d) 100 gm. of sodium bisulfite to l000 ml. of distilled water (maintained at room temperature), stirring the resulting mixture until all ingredients are dissolved, filtering through a Whatman filter paper (No. l and then adding 10 gms. of saponin to the filtered solution and stirring that mixture until dissolution is effected. The resultant solution is then dispensed in 2 ml. aliquot portions into l0 X mm. screw cap clear test tubes to which is then added 0.5 ml. of the organic phase, preferably toluene.
  • organic solvents capable of forming an immiscible organic phase on top of the liquid phase may also be used, among which solvents are n-pentane, hexane, heptane, octane, nonane, decane, undecane, tridecane, tetradecane, pentadecane, hexadecane, heptadecane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, allyl chloride, toluene, ethylbenzene, npropylbenzene, cumene, (isopropyl benzene), tert.
  • solvents are n-pentane, hexane, heptane, octane, nonane, decane, undecane, tridecane, tetradecane, pentadecane, hexade
  • reducing agents such as sodium metalbisulfite, cystine hydrochloride, ascorbic acid, hydrogen sulfide, 2,3-dimercapto propanol, glutathione, methylene blue, potassium ferrocyanide, thioglycolate, lactic acid and succinic acid may also be used. With the exception of the first three, most others are substantially less effective.
  • the literature also suggests other lysing agents (e. g.
  • each tube contains sufficient reactants for a single test and is stable for at least six months, both at room temperature and at 4C. This combination of features, of course, allows for both convenience and lack of waste, thereby reducing the overall cost of testing.
  • a microliter sample of blood (2-3 drops) is added to the reagent and the mixture shaken vigorously for a few seconds.
  • the tube is centrifuged.
  • centrifugation is at 3500-5000 r.p.m. for at least 2 minutes. Slower speeds for longer periods (i.e. 2500 r.p.m. for 5 minutes) may also be employed.
  • the centrifugation is nothing more than a method of phase separation.
  • this phase separation need not be accelerated by centrifugation.
  • the shaken mixture is allowed to stand until the phase separates, which generally takes about within l-2 hours.
  • the foregoing phase separation results in a two-layer system separated by a band in the middle; the aqueous phase is the lower phase and the organic layer is the upper phase.
  • the upper organic phase is immiscible with the aqueous phase and serves to bind sickling 3 hemoglobin to the liquid/liquid interface. This physical affinity is so strong that tipping over the tube (or inversion of the tube) often fails to disrupt the final pattern formed after phase separation.
  • the blood sample used can be fresh whole blood, whole blood with added anticoagulant, or hemoglobin preparations, either fresh or stored for several months.
  • the blood is obtained from a pricked-andbled finger.
  • the middle band is grey and the lower phase is red.
  • the hemoglobin genotype is AS the middle band is dark red and the lower phase is pink.
  • the hemoglobin genotype is SS the middle band is dark red and the lower phase is straw-colored or pale yellow.
  • a method for testing blood for the presence of Hemoglobin S which comprises vigorously admixing a blood sample with a two-phase test system and determining the presence or absence of Hemoglobin S after separation of the phases, said two-phase test system comprising (a) an aqueous phase containing on a weight/volume basis of about 3845 percent total solids, said total solids consisting of a lysing agent in amounts up to about 2 percent of the total solids, a chemical reducing system in amounts up to about 22.4 percent of the total solids and a phosphate ion buffer system in amounts up to about 75.6 percent of the total solids, and (b) an organic phase immiscible with and lighter than said aqueous phase; the Hemoglobin S characteristic being determinable by the color of a band formed at the interface of the organic and aqueous phases and the hemoglobin genotype AS being determinable from the hemoglobin genotype SS by the color of the aqueous phase.
  • test procedure forms a distinguishing band at the interface of the two phases after a blood sample has been vigorously admixed with the test system.
  • the phosphate ion buffer system consists of dibasic potassium phosphate and monobasic potassium phosphate in weight/weight proportions of 1.75/ l .0, respectively, said aqueous phase having a hydrogen ion concentration capable of providing a pH of about 6.3 (10.15).
  • a composition suitable for testing whole blood for Hemoglobin S comprising (a) an aqueous phase having a total solids content (weight/volume) of about 3845 percent and (b) an organic phase immiscible with and lighter than said aqueous phase, said aqueous phase capable of producing a hydrogen ion content sufficient to effect a pH of 6.3 (10.15), said aqueous phase containing a phosphate ion buffer system in amounts up to about 75.6 percent of the total solids content, a lysing agent in amounts up to about 2 percent of the total solids content and a chemical reducing system in amounts up to about 22.4 of the total solids content.
  • composition of claim 5 wherein said lysing agent is saponin.
  • composition of claim 5 wherein said organic phase is toluene.
  • composition of claim 5 wherein the chemical reducing system is composed of sodium bisulfite and sodium hydrosulfite, said sodium bisulfite being present in amounts up to about ten times as much as the amount present of sodium hydrosulfite.

Abstract

A novel composition comprising an aqueous and an organic phase, the aqueous phase comprising essentially a phosphate buffering system containing a stable reducing agent and a lysing agent, the composition providing for a test for the determination of sickling hemoglobin that is simple to perform, is stable, convenient, reliable, fast and one that differentiates between heterozygous Hemoglobin S and homozygous Hemoglobin S without false positives or false negatives.

Description

United States Patent [191 Warren et a1.
1541 DIAGNOSTIC TEST FOR THE DETERMINATION OF SICKLING HEMOGLOBINOPATIIIES [75] Inventors: Bert Warren, Tuxedo Park. N.Y.;
Gordon Crosby, Jr., East Orange; George L. Evans, Hoptaeong. both of NJ.
[73] Assignee: Biological Corporation of America,
Port Reading. NJ.
Filed. July 20, 1973 Appl. No: 381.299
[521 US. Cl. 23/230 B; 252/408 [51] Int. Cl. GOIN 33/16; GOlN 21/06 [58] Field of Search 23/230 B. 252/408;
[56] References Cited UNITED STATES PATENTS 3.4921195 1/1970 Tillem 23/330 B 5] Nov. 11, 1975 3.607.695 9/1971 Schneider......... 2312.) B X 3.761.126 9/1973 Louderhack et a1 23/1) B 3.847.545 11/1974 Shanbrom et a1. 23/3311 B OTHER PUBLICATIONS The Merck Index. 7th Ed. pp. 946. 953 (1960). C1in.Chem..\ o1. 17(11). pp. 1081-1082 (1971). C1in.Chem..Vo1. 17(10). pp. 1028-1032 (1971).
Primary E.\'umiawMorris O. Wolk Assismnl Examiner-Timoth W. Hagen [57] ABSTRACT A novel composition comprising an aqueous and an organic phase. the aqueous phase comprising essentially a phosphate buffering system containing a stable reducing agent and a lysing agent. the composition providing for a test for the determination of sickling hemoglobin that is simple to perform. is stable. convenient. reliable. fast and one that differentiates between heteroz gous Hemoglobin S and homozygous Hemoglobin 5 without false positives or false negatnes.
9 Claims. N0 Drawings DIAGNOSTIC TEST FOR THE DETERMINATION OF SICKLING HEMOGDOBINOPATHIES This invention relates to a novel screening composition suitable for accurately and reliably determining the presence of sickling hemoglobin and for accurately and easily determining whether the patient having sickling hemoglobin is heterozygous or homozygous.
As is well known, it is essential in clinical diagnosis to determine the presence of Hemoglobin S and, once sodetermined, to detect whether the patient has sicklecell anemia (i.e., SS or homozygous) or sickle-cell trait (i.e., AS or heterozygous). As is also well known, several systems for this determination have been developed but such prior art systems have, in one aspect or another, failed to meet the desired criteria for the efficient applicability for both field and laboratory use. It is believed that the composition of the instant invention does meet the criteria for such uses and offers such advantages that neither the laboratory nor the field technicians need prepare his own reagent. In essence, the procedure facilitates unit packaging at a manufacturers level, is simple and rapid, provides for reagent stability of up to 2 months, has an endpoint stability which provides for reading the results even after periods of up to 6 weeks, does not require the use of any viewing devices and affords the presumptive identification of normal (AA), trait (AS), and disease (SS) hemoglobin genotypes with an increase in reliability. Additionally, the instant invention has possible application for the determination of such blood characteristics in newbrons. Thus, the composition has value for rapidly screening samples newborns. routine practice, for medical emergencies and in the practice of pediatric medicine.
In general, the composition is comprised of an aqueous phase containing a phosphate buffer system, a stable reducing agent system and a lysing agent, said aqueous phase being in combination with an organic phase which is immiscible with the aqueous phase.
More specifically, this invention relates to a twophase composition comprised of an aqueous phase and an organic phase wherein the aqueous phase is comprised of about 38-45 percent solids (on a weight- [volume basis) having a hydrogen ion content sufficient to provide a pH value of about 6.3 said solids being comprised of (a) a lysing agent providing for up to about 2 percent of the total solids content (b) a mixture of chemical reducing agents providing for up to about 22.4 percent of the total solids content and (c) a phosphate ion bufier system providing the remaining total solids (75.6 percent) present in the aqueous phase. The phosphate ion is provided by dibasic alkali metal phosphate (preferably dibasic potassium phosphate) and monobasic alkali metal phosphate (preferably monobasic potassium phosphate) in the weight/- weight ration of 1.75 of the dibasic phosphate to 1.0 of the monobasic phosphate. The organic phase, added after the aqueous phase has been aliquoted, is preferably in the volume/volume ration of 1 part organic phase to 4 parts aqueous phase. Although minor variations are possible, it is preferred to employ a total solids content in the aqueous phase within the range of 38-45percent solids, with 41 percent being most preferred. Upwards variations in the total solids of about 10 percent over the foregoing range gives false positives, while downward variations of about 10 percent of the foregoing range will give false negatives. The most preferred 2 stable chemical reducing system is provided for by combining sodium hydrosulfite and sodium bisulfite in the sodium hydrosulfite/sodium bisulfite ratio of l/ 10 (wt./wt.).
The preparation of the most preferred formulation is effected by adding (a) 237 gms. of dibasic potassium phosphate, (b) l35 gm. of monobasic potassium phosphate, (c) 10 gm. of sodium hydrosulfite and (d) 100 gm. of sodium bisulfite to l000 ml. of distilled water (maintained at room temperature), stirring the resulting mixture until all ingredients are dissolved, filtering through a Whatman filter paper (No. l and then adding 10 gms. of saponin to the filtered solution and stirring that mixture until dissolution is effected. The resultant solution is then dispensed in 2 ml. aliquot portions into l0 X mm. screw cap clear test tubes to which is then added 0.5 ml. of the organic phase, preferably toluene.
As noted, the foregoing formulation is the most preferred. Other organic solvents capable of forming an immiscible organic phase on top of the liquid phase may also be used, among which solvents are n-pentane, hexane, heptane, octane, nonane, decane, undecane, tridecane, tetradecane, pentadecane, hexadecane, heptadecane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, allyl chloride, toluene, ethylbenzene, npropylbenzene, cumene, (isopropyl benzene), tert. butyl benzene, o-xylene, m-xylene, and p-xylene, (It should be noted that such organic solvents (especially toluene) may also be used as lysing agents, although saponin is still most preferred.)
Other reducing agents such as sodium metalbisulfite, cystine hydrochloride, ascorbic acid, hydrogen sulfide, 2,3-dimercapto propanol, glutathione, methylene blue, potassium ferrocyanide, thioglycolate, lactic acid and succinic acid may also be used. With the exception of the first three, most others are substantially less effective. The literature also suggests other lysing agents (e. g. digitonin, sodium lauryl sulfate, Tween 20, ethylhexadecyl methyl-ammonium bromide, palmitoyl-D, L-carnitine, palmitoyl choline and (lpalmitoyl), lysolecithin and many others, but saponin is most effective.
Once prepared, the composition is very easily used. In practice, each tube contains sufficient reactants for a single test and is stable for at least six months, both at room temperature and at 4C. This combination of features, of course, allows for both convenience and lack of waste, thereby reducing the overall cost of testing.
To perform the test, a microliter sample of blood (2-3 drops) is added to the reagent and the mixture shaken vigorously for a few seconds. After allowing for the chemical reduction of the hemoglobin (i.e. the hemoglobin turns reddishpurple after about 3 minutes) the tube is centrifuged. Preferably, centrifugation is at 3500-5000 r.p.m. for at least 2 minutes. Slower speeds for longer periods (i.e. 2500 r.p.m. for 5 minutes) may also be employed.
Of course, the centrifugation is nothing more than a method of phase separation. In view of the stability afforded by this test procedure, this phase separation need not be accelerated by centrifugation. [n such instances the shaken mixture is allowed to stand until the phase separates, which generally takes about within l-2 hours. The foregoing phase separation results in a two-layer system separated by a band in the middle; the aqueous phase is the lower phase and the organic layer is the upper phase. The upper organic phase is immiscible with the aqueous phase and serves to bind sickling 3 hemoglobin to the liquid/liquid interface. This physical affinity is so strong that tipping over the tube (or inversion of the tube) often fails to disrupt the final pattern formed after phase separation. On those random occasions wherein a pattern is accidentally disrupted, it can be re-separated. Of course, in each instance, it is most preferred to accelerate the phase separation by the above-described centrifugation technique, non-use being preferably limited to those situations wherein a centrifuge is unavailable. Experience has shown that those samples which are centrifuged produce a very tight, more easily recognized, band at the interface as well as producing a more stable two-phase system.
The blood sample used can be fresh whole blood, whole blood with added anticoagulant, or hemoglobin preparations, either fresh or stored for several months. Preferably, the blood is obtained from a pricked-andbled finger.
The results are read as follows:
With normal blood the middle band is grey and the lower phase is red. When the hemoglobin genotype is AS the middle band is dark red and the lower phase is pink. When the hemoglobin genotype is SS the middle band is dark red and the lower phase is straw-colored or pale yellow.
We claim:
1. A method for testing blood for the presence of Hemoglobin S which comprises vigorously admixing a blood sample with a two-phase test system and determining the presence or absence of Hemoglobin S after separation of the phases, said two-phase test system comprising (a) an aqueous phase containing on a weight/volume basis of about 3845 percent total solids, said total solids consisting of a lysing agent in amounts up to about 2 percent of the total solids, a chemical reducing system in amounts up to about 22.4 percent of the total solids and a phosphate ion buffer system in amounts up to about 75.6 percent of the total solids, and (b) an organic phase immiscible with and lighter than said aqueous phase; the Hemoglobin S characteristic being determinable by the color of a band formed at the interface of the organic and aqueous phases and the hemoglobin genotype AS being determinable from the hemoglobin genotype SS by the color of the aqueous phase.
2. A process according to claim 1 wherein the test procedure forms a distinguishing band at the interface of the two phases after a blood sample has been vigorously admixed with the test system.
3. A method according to claim 1 wherein the phosphate buffer system is present in the aqueous phase in the amount of about 3l percent (weight/volume).
4. A process according to claim 1 wherein the phosphate ion buffer system consists of dibasic potassium phosphate and monobasic potassium phosphate in weight/weight proportions of 1.75/ l .0, respectively, said aqueous phase having a hydrogen ion concentration capable of providing a pH of about 6.3 (10.15).
5. A composition suitable for testing whole blood for Hemoglobin S comprising (a) an aqueous phase having a total solids content (weight/volume) of about 3845 percent and (b) an organic phase immiscible with and lighter than said aqueous phase, said aqueous phase capable of producing a hydrogen ion content sufficient to effect a pH of 6.3 (10.15), said aqueous phase containing a phosphate ion buffer system in amounts up to about 75.6 percent of the total solids content, a lysing agent in amounts up to about 2 percent of the total solids content and a chemical reducing system in amounts up to about 22.4 of the total solids content.
6. A composition of claim 5 wherein said lysing agent is saponin.
7. A composition of claim 5 wherein said organic phase is toluene.
8. A composition of claim 5 wherein the chemical reducing system is composed of sodium bisulfite and sodium hydrosulfite, said sodium bisulfite being present in amounts up to about ten times as much as the amount present of sodium hydrosulfite.
9. A composition of claim 5 wherein the dibasic potassium phosphate is present in amounts up to 1.75
times the amount of monobasic potassium phosphate.

Claims (9)

1. A METHOD FOR TESTING BLOOD FOR THE PRESENCE OF HEMOGLOBIN S WHICH COMPRISES VIGOROUSLY ADMIXING A BLOOD SAMPLE WITH A TWO-PHASE TEST SYSTEM AND DETERMINING THE PRESENCE OR ABSENCE OF HEMOGLOBIN S AFTER SEPARATION OF THE PHASES, SAID TWO-PHASE SYSTEM COMPRISING (A) AN AQUEOUS PHASE CONTAINING ON A WEIGHT-VOLUME BASIS OF ABOUT 38-45 PERCENT TOTAL SOLIDS, SAID TOTAL SOLIDS CONSISTING OF A LYSING AGENT IN AMOUNTS UP TO ABOUT 2 PERCENT OF THE TOTAL SOLIDS, A CHEMICAL REDUCING SYSTEM IN AMOUNTS UP TO ABOUT 22.4 PERCENT OF THE TOTAL SOLIDS AND A PHOSPHATE ION BUFFER SYSTEM IN AMOUNTS UP TO ABOUT 75.6 PERCENT OF TE TOTAL SOLIDS,AND (B) AN ORGANIC PHASE IMMISCIBLE WITH AND LIGHTER THAN SAID AQUEOUS PHAS, THE HEMOGLOBIN S CHARACTERISTIC BEING DETERMINABLE BY THE COLOR OF A BAND FORMED AT THE INTERFACE OF THE ORGANIC AND AQUEOUS PHASES AND THE HEMOGLOBIN GENOTYPE AS BEING DETERMINABLE FROM THE HEMOGLOBIN GENOTYPE SS BY THE COLOR OF THE AQUEOUS PHASE.
2. A process according to claim 1 wherein the test procedure forms a distinguishing band at the interface of the two phases after a blood sample has been vigorously admixed with the test system.
3. A method according to claim 1 wherein the phosphate buffer system is present in the aqueous phase in the amount of about 31 percent (weight/volume).
4. A process according to claim 1 wherein the phosphate ion buffer system consists of dibasic potassium phosphate and monobasic potassium phosphate in weight/weight proportions of 1.75/1.0, respectively, said aqueous phase having a hydrogen ion concentration capable of providing a pH of about 6.3 ( + or -0.15).
5. A composition suitable for testing whole blood for Hemoglobin S comprising (a) an aqueous phase having a total solids content (weight/volume) of about 38-45 percent and (b) an organic phase immiscible with and lighter than said aqueous phase, said aqueous phase capable of producing a hydrogen ion content sufficient to effect a pH of 6.3 ( + or - 0.15), said aqueous phase containing a phosphate ion buffer system in amounts up to about 75.6 percent of the total solids content, a lysing agent in amounts up to about 2 percent of the total solids content and a chemical reducing system in amounts up to about 22.4 % of the total solids content.
6. A composition of claim 5 wherein said lysing agent is saponin.
7. A composition of claim 5 wherein said organic phase is toluene.
8. A composition of claim 5 wherein the chemical reducing system is composed of sodium bisulfite and sodium hydrosulfite, said sodium bisulfite being present in amounts up to about ten times as much as the amount present of sodium hydrosulfite.
9. A composition of claim 5 wherein the dibasic potassium phosphate is present in amounts up to 1.75 times the amount of monobasic potassium phosphate.
US381299A 1973-07-20 1973-07-20 Diagnostic test for the determination of sickling hemoglobinopathies Expired - Lifetime US3918905A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US381299A US3918905A (en) 1973-07-20 1973-07-20 Diagnostic test for the determination of sickling hemoglobinopathies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US381299A US3918905A (en) 1973-07-20 1973-07-20 Diagnostic test for the determination of sickling hemoglobinopathies

Publications (1)

Publication Number Publication Date
US3918905A true US3918905A (en) 1975-11-11

Family

ID=23504498

Family Applications (1)

Application Number Title Priority Date Filing Date
US381299A Expired - Lifetime US3918905A (en) 1973-07-20 1973-07-20 Diagnostic test for the determination of sickling hemoglobinopathies

Country Status (1)

Country Link
US (1) US3918905A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200435A (en) * 1978-12-26 1980-04-29 Abbott Laboratories Determination of glycosylated hemoglobin in blood
FR2445529A1 (en) * 1978-12-26 1980-07-25 Coulter Electronics PROCESS FOR THE PREPARATION OF A STABLE CALIBRATION COMPOSITION, COMPOSITION OBTAINED AND USE OF A HALOPHENOL FOR STABILIZATION
US4297238A (en) * 1978-11-22 1981-10-27 Merck Patent Gesellschaft Mit Beschrankter Haftung Hemolysing solution preparing hemolysed blood having a stabilized glucose content
US4336157A (en) * 1980-06-27 1982-06-22 Baxter Travenol Laboratories, Inc. Process for reclaiming biliverdin-containing fluids
US5514592A (en) * 1995-02-13 1996-05-07 Medicus Technologies, Inc. Method and composition for testing blood for hemoglobin S that incorporates mineral oil as an insoluble upper phase
US20120077218A1 (en) * 2010-09-24 2012-03-29 Saint Louis University Sickle confirm modified hemoglobin solubility test
CN110583573A (en) * 2019-09-24 2019-12-20 山西大学 Construction and evaluation method of blood deficiency mouse model

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492095A (en) * 1967-10-05 1970-01-27 Harold B Tillen Product for and method of testing blood for the presence of hemoglobin s
US3607695A (en) * 1969-02-14 1971-09-21 Pfizer & Co C Hemoglobinopathy controls
US3761226A (en) * 1972-03-24 1973-09-25 Baxter Laboratories Inc Sickel cell diagnostic test
US3847545A (en) * 1972-05-18 1974-11-12 Baxter Laboratories Inc Diagnostic test for sickle-cell

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492095A (en) * 1967-10-05 1970-01-27 Harold B Tillen Product for and method of testing blood for the presence of hemoglobin s
US3607695A (en) * 1969-02-14 1971-09-21 Pfizer & Co C Hemoglobinopathy controls
US3761226A (en) * 1972-03-24 1973-09-25 Baxter Laboratories Inc Sickel cell diagnostic test
US3847545A (en) * 1972-05-18 1974-11-12 Baxter Laboratories Inc Diagnostic test for sickle-cell

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297238A (en) * 1978-11-22 1981-10-27 Merck Patent Gesellschaft Mit Beschrankter Haftung Hemolysing solution preparing hemolysed blood having a stabilized glucose content
US4200435A (en) * 1978-12-26 1980-04-29 Abbott Laboratories Determination of glycosylated hemoglobin in blood
FR2445529A1 (en) * 1978-12-26 1980-07-25 Coulter Electronics PROCESS FOR THE PREPARATION OF A STABLE CALIBRATION COMPOSITION, COMPOSITION OBTAINED AND USE OF A HALOPHENOL FOR STABILIZATION
US4250051A (en) * 1978-12-26 1981-02-10 Coulter Electronics, Inc. Preservative for use in calibrator compositions for blood analysis
US4336157A (en) * 1980-06-27 1982-06-22 Baxter Travenol Laboratories, Inc. Process for reclaiming biliverdin-containing fluids
US5514592A (en) * 1995-02-13 1996-05-07 Medicus Technologies, Inc. Method and composition for testing blood for hemoglobin S that incorporates mineral oil as an insoluble upper phase
US20120077218A1 (en) * 2010-09-24 2012-03-29 Saint Louis University Sickle confirm modified hemoglobin solubility test
US8623659B2 (en) * 2010-09-24 2014-01-07 Saint Louis University Sickle confirm modified hemoglobin solubility test
CN110583573A (en) * 2019-09-24 2019-12-20 山西大学 Construction and evaluation method of blood deficiency mouse model
CN110583573B (en) * 2019-09-24 2020-08-04 山西大学 Construction and evaluation method of blood deficiency mouse model

Similar Documents

Publication Publication Date Title
Beutler et al. The hemolytic effect of primaquine: VI. An in vitro test for sensitivity of erythrocytes to primaquine
Kruse-Jarres et al. Trace elements in diabetes mellitus. Peculiarities and clinical validity of determinations in blood cells
Brewer et al. Methaemoglobin reduction test: a new, simple, in vitro test for identifying primaquine-sensitivity
US4615972A (en) Stabilization of indicators for detecting enzyme activity
Laessig et al. The effects of 0.1 and 1.0 percent erythrocytes and hemolysis on serum chemistry values
CA1087966A (en) Process and a metachromatic composition for effecting a count of leucocytes, and more particularly of basophiles
US3918905A (en) Diagnostic test for the determination of sickling hemoglobinopathies
EP0185335B1 (en) Method for the determination of an allergy and method for the specific determination of the allergen responsible for the allergy
US3847545A (en) Diagnostic test for sickle-cell
Bloch Human Erythrocyte Sugar Transport: KINETIC EVIDENCE FOR AN ASYMMETRIC CARRIER
Brunetti et al. A screening method for the detection of erythrocyte pyruvate kinase deficiency
Dowben et al. Erythrocyte electrolytes in muscle disease
Holzbecher et al. An evaluation and modification of a microdiffusion method for the emergency determination of blood cyanide
Venkataraman et al. Method for the estimation of acetylisoniazid in urine
Qazi et al. A simple rapid test for lead poisoning
US3761226A (en) Sickel cell diagnostic test
Rogers et al. Erythrocyte enzymes in experimental lead poisoning
Fattoum et al. Some data on the epidemiology of hemoglobinopathies in Tunisia
US5514592A (en) Method and composition for testing blood for hemoglobin S that incorporates mineral oil as an insoluble upper phase
Sirchia et al. Red cell acetylcholinesterase activity in autoimmune haemolytic anaemias
Lijnen et al. Intracellular concentration and transmembrane fluxes of sodium and potassium in erythrocytes of white normal male subjects with and without a family history of hypertension
Rassiga-Pidot et al. Paroxysmal nocturnal hemoglobinuria with elevated fetal hemoglobin
Tucker et al. The M‐L blood group system and active potassium transport in sheep reticulocytes
Songu-Mize et al. Race, sex, and family history of hypertension and erythrocyte sodium pump [3H] ouabain binding.
Cassidy et al. Calcium and magnesium contents of gastrointestinal tissues in six species

Legal Events

Date Code Title Description
AS Assignment

Owner name: BHP DIAGNOSTIX, INC., 237 LACEY STREET, WEST CHEST

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:COOPERBIOMEDICAL, INC. A DE CORP;REEL/FRAME:004400/0607

Effective date: 19850503

STCF Information on status: patent grant

Free format text: PATENTED FILE - (OLD CASE ADDED FOR FILE TRACKING PURPOSES)